UNSPSC 51152007: Doxacurium

This classification denotes a muscle relaxant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M78TVM3G5Z. European Medicines Agency schedules Doxacurium chloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06380MIG. Doxacurium chloride generally arises in the molecular formula C56H78CL2N2O16.

The term DOXACURIUM CHLORIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) As of Q4 2014, DOXACURIUM remains the US FDA Preferred Term for this commodity. Doxacurium bears US NLM identifiers UMLS ID C0058716 and NCI Concept Code C81000. SMILES: C[N+]1(CCC2=CC(=C(C(=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)OC)CCCOC(=O)CCC(=O)OCCC[N+]4(CCC5=CC(=C(C(=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)OC)C.[CL-].[CL-].

UNSPSC 51152007 Doxacurium (Commodity) represents pharmaceutical products and related drug-delivery systems that state and local health authorities procure to support emergency response and community health programs. The recent solicitation activity under this code reflects state and local governments' focus on acquiring naloxone (opioid-reversal medication) and drug deactivation systems for public health deployment, though the code's nominal scope (doxacurium, a neuromuscular blocking agent) diverges significantly from what is actually being bought. Issuing bodies include county health departments and state health and human services agencies purchasing these products through competitive bidding processes to stock emergency response capabilities and community health infrastructure.

Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB with a July 26, 2023 response deadline, with quarterly deliveries to the Seminole County Community Health Building and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for implementing therapeutic pharmacy initiatives outside traditional pharmacy benefit manager and group purchasing organization channels. Activity concentrates in Florida and Texas, with both solicitations emphasizing compliance requirements (E-Verify, drug-free workplace certification, federal environmental regulations when FEMA-funded) and fixed-fee or negotiated net-pricing models. The recent opportunities show state and local governments using this code category for emergency medical supplies and pharmacy program structuring rather than the specific neuromuscular agent the code nominally describes.